VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 10,079 shares, a growth of 148.0% from the June 30th total of 4,064 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average trading volume of 4,959 shares, the days-to-cover ratio is currently 2.0 days.

Insider Activity

In other news, major shareholder Sardar Biglari sold 11,000 shares of VanEck Biotech ETF stock in a transaction on Friday, July 17th. The stock was sold at an average price of $16.71, for a total value of $183,810.00. Following the transaction, the insider directly owned 3,538,961 shares in the company, valued at approximately $59,136,038.31. This trade represents a 0.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 21,493 shares of company stock valued at $359,145.

Institutional Trading of VanEck Biotech ETF

Hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. boosted its stake in VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after acquiring an additional 492,843 shares in the last quarter. Raymond James Financial Inc. raised its stake in VanEck Biotech ETF by 2.8% in the third quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock valued at $11,566,000 after buying an additional 1,869 shares during the last quarter. Bank of America Corp DE raised its stake in VanEck Biotech ETF by 44.3% in the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after buying an additional 20,375 shares during the last quarter. Ascent Advisors LLC acquired a new stake in VanEck Biotech ETF in the first quarter worth about $11,178,000. Finally, LPL Financial LLC boosted its holdings in VanEck Biotech ETF by 63.5% in the fourth quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock worth $6,021,000 after acquiring an additional 12,351 shares in the last quarter. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ BBH opened at $204.74 on Tuesday. VanEck Biotech ETF has a 1-year low of $156.45 and a 1-year high of $212.54. The business has a fifty day moving average price of $195.31 and a 200 day moving average price of $192.49.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.